Biosimilars offer additional treatment options for patients with IBD. In this activity, faculty will review the role of biosimilars in the management of IBD and answer learner questions from the previous CME activity.

Find this FREE CME Activity here: www.cmecorner.com/biosimilars

Faculty

Russell D. Cohen, MD, FACG, AGAF
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
The University of Chicago Medicine
Professor of Medicine
Pritzker School of Medicine
Chicago, IL

Sushila Dalal, MD
Inflammatory Bowel Disease Center
The University of Chicago Medicine
Assistant Professor of Medicine
Pritzker School of Medicine
Chicago, IL

CCME Reviewer:
Thomas A. Ullman, MD
Professor of Medicine
Chief, Division of Gastroenterology
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, NY

Credit Hours

0.5

Medium

Video Roundtable

Program Description

Biosimilars offer additional treatment options for patients with IBD. In this activity, faculty will review the role of biosimilars in the management of IBD and answer learner questions from the previous activity (see “Related Programs” above).

Program Developer/Facilitator

This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.

Target Audience

Gastroenterologists, primary care physicians, NPs, PAs, and other healthcare providers who care for patients with IBD.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe how biosimilars are similar to and different from their originator biologic.
  2. Identify biosimilars approved for the treatment of patients with IBD.
  3. Discuss how the use of biosimilars contributes to value-based care.

Disclosures

The Albert Einstein College of Medicine also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.

Faculty Disclosures

Russell D. Cohen, MD, FACG, AGAF
Speakers bureau: AbbVie, Takeda
Consultant: AbbVie, Celgene, Entera Health, Hospira, Janssen, Pfizer Inc., Sandoz, Takeda, UCB
Research support: AstraZeneca, Celgene, Gilead Sciences, MedImmune, Mesoblast, Osiris Therapeutics, Pfizer Inc., Receptos, RedHill Biopharma, Sanofi US, UCB

Sushila Dalal, MD
Research support: Pfizer Inc., Takeda

Thomas A. Ullman, MD
Consultant: Pfizer Inc.

The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests relative to this CME activity.

Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose.